



Jfw
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Denis Gravel *et al.*

Serial No.: 10/727,119

Filed: December 3, 2003

For: DERIVATIVES OF SUCCINIC AND
GLUTARIC ACIDS AND ANALOGS
THEREOF USEFUL AS INHIBITORS OF
PHEX

Group Art Unit: 1626

Examiner: Unknown

Atty. Dkt. No.: GOUD:045US

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

August 18, 2004

Date

Michael R. Krawzsenek
Michael R. Krawzsenek

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/GOUD:045US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Michael R. Krawzsenek".

Michael R. Krawzsenek
Reg. No. 51,898
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: August 18, 2004



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

MKRAWZSENEK@FULBRIGHT.COM
DIRECT DIAL: (512) 536-3020

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

August 18, 2004

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

August 18, 2004

Date

Michael R. Krawzsenek

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/727,119 entitled "DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX" – Denis Gravel et al.*
Our reference: GOUD:045US
Client reference: 769/12987.28

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references B2-B12 and C38-C46.


No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/GOUD:045US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Michael R. Krawzsenek
Reg. No. 51,898

MRK/kmv
Encl.: as noted



Form PTO-1449 (modified)		Atty. Docket No. GOUD:045US	Serial No. 10/727,119
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Denis Gravel et al.	
		Filing Date: December 3, 2003	Group: 1626
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B2	EP 0 254 032	1/27/88	Europe			English
	B3	EP 0 412 595	2/13/91	Europe			English
	B4	EP 0 566 157	10/20/93	Europe			English
	B5	FR 2372804	6/30/78	France			Abstract
	B6	FR 2377374	8/11/78	France			Abstract
	B7	WO 00/5080	8/31/00	PCT			English
	B8	WO 02/092128	11/21/02	PCT			English
	B9	WO 02/15918	2/28/02	PCT			English
	B10	WO 03/084997	10/16/03	PCT			English
	B11	WO 97/05865	2/20/97	PCT			English
	B12	WO 99/11606	3/11/99	PCT			English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C38	Boileau <i>et al.</i> , "Characterization of PHEX endopeptidase catalytic activity: identification of parathyroid-hormone-related peptide ₁₀₇₋₁₃₉ as a substrate and osteocalcin, PP _i and phosphate as inhibitors," <i>Biochem. J.</i> , 355:707-713, 2001.
	C39	Chapman <i>et al.</i> , "Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides," <i>J. Medicinal Chemistry</i> , abstract, 36(26):4293-4301, 1993.

25444629.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. GOUD:045US	Serial No. 10/727,119
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Denis Gravel et al.	
		Filing Date: December 3, 2003	Group: 1626
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C40	Elgazwy and Abdel-Sattar, "Facile synthesis of (R,R) and of (R,S) tricarballic acid anhydride and imide derivatives," <i>Molecules</i> , abstract, 5(4):665-673, 2000.
	C41	Fourine-Zaluski <i>et al.</i> , "Differential recognition of 'enkephalinase' and angiotensin-converting enzyme by new carboxyalkyl inhibitors," <i>Life Sciences</i> , 31:2947-2954, 1982.
	C42	Mimura <i>et al.</i> , "A novel class of enkephalinase inhibitors containing a C-terminal sulfo group," <i>J. Med. Chem.</i> , 35:602-608, 1992.
	C43	Ovens <i>et al.</i> , "Design and synthesis of acidic dipeptide hydroxamate inhibitors of procollagen C-proteinase," <i>J. Peptide Science</i> , abstract 6(9):489-495, 2000.
	C44	Rinnova <i>et al.</i> , "An expedient method for the solid-phase synthesis of alpha-aminoalkyl phosphonopeptides," <i>Tetrahedron Lett</i> , abstract, 43(22):4103-4106, 2002.
	C45	Rowe, "The role of the phex gene (PEX) in families with X-linked hypophosphataemic rickets," <i>Curr. Opin Nephrol Hypertens</i> , 7:367-376, 1998.
	C46	Serval <i>et al.</i> , "In vitro and in vivo inhibition of N-acetyl-L-aspartyl-L-glutamate catabolism by N-acylated L-glutamate analogs," <i>J. Pharmacology and Experimental Therapeutics</i> , abstract, 260(3):1093-1100, 1992.

25444629.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.